XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
Parkinson’s Disease
Advertisement
Parkinson’s IQ + You Empowers Nevada Patients
February 24, 2026 – New York, USA The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced that...
Jupiter Neurosciences Aligns Capital With Clinical Growth
JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...
Single-Molecule Proteomics Targets Alpha-Synuclein in Parkinson’s
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
IRLAB and Biomia Partner to Advance CNS Drug Discovery
GOTHENBURG, Sweden | January 19, 2026 — IRLAB Therapeutics AB, a clinical-stage company focused on novel treatments for Parkinson’s...
Advertisements
IRLAB Wins Approval for Phase Ib IRL757 Parkinson’s Trial
Gothenburg, Sweden | December 23, 2025 — IRLAB Therapeutics AB announced that it has received regulatory and ethical approvals...
AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
Aspen Neuroscience Secures $115M to Advance Cell Therapy
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
FDA Clears Jupiter Neurosciences’ JOTROL™ for Phase 2a Parkinson’s Trial
JUPITER, Florida, November 5, 2025 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company, announced that the U.S....
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Advertisement
